Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Dec 11, 2019
|
staff reporter

NEW YORK – Eli Lilly announced on Wednesday that its Phase III LIBRETTO-431 trial for the initial treatment of advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) is now openly enrolling patients. Enrollment will be capped at 400 participants.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Cancer

  1. Myriad Genetics BRCA Test to be Reimbursed in Japan

  2. Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing

    Premium

  3. European Commission Approves Takeda's Alunbrig for First-Line ALK-positive Lung Cancer

  4. Breast Cancer Subtypes Vary With Indigenous Ancestry in Latin American Women

  5. Sequencing, Molecular Tumor Board Enable Precision Therapy for GI Cancer Patients, Study Shows

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.